A recent peer-reviewed publication in Stereotactic and Functional Neurosurgery details the clinical experience with NeuroOne Medical Technologies Corporation's OneRF Ablation System, the first FDA-cleared system for stereoelectroencephalography-guided radiofrequency ablation. The case series, accessible via PubMed at https://pubmed.ncbi.nlm.nih.gov/41785222/, reports on four consecutive patients with drug-resistant epilepsy treated at a leading U.S. epilepsy center, highlighting the system's safety, workflow integration, and therapeutic potential.
The authors describe the procedure as safe and easily integrated into existing stereotactic neurosurgical workflows, with the flexibility to perform treatment either in the operating room or at the patient's bedside in the epilepsy monitoring unit. A key technological advancement is the system's ability to perform RF ablation without removing or repositioning already implanted sEEG electrodes. Treatment is delivered directly through these implanted electrodes while monitoring temperature in real time, enabling precise, controlled lesion creation while minimizing risk to surrounding brain structures. The publication reported no adverse events, and all four patients experienced reductions in seizure burden following treatment.
Beyond its therapeutic application, the procedure provided valuable information that helped guide subsequent surgical decision-making for these patients. This dual diagnostic and prognostic capability underscores the system's potential value in the comprehensive management of intractable epilepsy. The authors note in their publication that this development represents a significant advancement for patients undergoing sEEG for invasive evaluation. The OneRF Ablation System is NeuroOne's first device with a therapeutic indication and the company's third FDA 510(k)-cleared device, complementing their existing line of thin film electrode technology for diagnostic brain mapping.
The implications of this clinical validation are substantial for the medical device industry and patient care. NeuroOne estimates the combined sEEG and brain ablation market to be at least $200 million worldwide and growing, with potential for multifold growth given large addressable patient populations with unmet clinical needs. For patients suffering from drug-resistant epilepsy, this technology offers a minimally invasive option that could reduce the number of required surgical procedures and hospitalizations, potentially lowering overall healthcare costs while improving patient outcomes. The ability to perform diagnostic mapping and therapeutic ablation in a single procedure represents a paradigm shift in neurological intervention, moving toward more integrated and efficient treatment pathways for complex brain disorders.
